US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP], mitochondrial.
- Target
- Isocitrate dehydrogenase [NADP], mitochondrial
- Mechanism
- Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
pharma · Pyruvate Kinase Deficiency · Sickle Cell Disease · AGIO
Agios Netherlands
Agios Netherlands B.V.
Agios Netherlands drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CAMBRIDGE, MA, NL HQ
1978 Founded
20 Employees
Public company Type
AGIO · NYSE Ticker
Company details
- Status
- Public
- HQ
- CAMBRIDGE, MA, NL
- Founded
- 1978
- Employees
- 20
- Programs
- 1
- Drugs
- 8
- Patents
- 24
Agios Netherlands pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Agios Netherlands drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
ivosidenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP] cytoplasmic.
- Target
- Isocitrate dehydrogenase [NADP] cytoplasmic
- Mechanism
- Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
-
mitapivat
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Agios Netherlands's portfolio. Molecular target: Pyruvate kinase PKLR.
- Target
- Pyruvate kinase PKLR
- Mechanism
- Pyruvate kinase isozymes R/L activator
-
US regulatory status: approved. Molecular target: Pyruvate kinase PKLR.
- Target
- Pyruvate kinase PKLR
- Mechanism
- Pyruvate kinase isozymes R/L activator
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
vorasidenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: IDH1/IDH2.
- Target
- IDH1/IDH2
- Mechanism
- IDH1/IDH2 inhibitor